진행성 비소세포폐암 환자에서 Gefitinib와 Erlotinib의 비교 = Comparison of Gefitinib and Erlotinib for Patients with Advanced Non-Small-Cell Lung Cancer

국문 초록 (Abstract)

연구배경: 표피성장인자수용체(epidermal growth factor receptor, EGFR) 티로신 활성효소 억제제(tyrosine kinase inhibitor, TKI)는 진행성 비소세포폐암의 새로운 치료제이다. 몇몇 연구 결과 gefitinib와 erlotinib에 대한 반응률과 반응 예측인자에 차이가 있을 가능성을 제시하였다. 저자들은 한국인 진행성 비소세포폐암에서 gefitinib와 erlotinib의 효과 및 독성을 비교하고 각 약제에 대해 서로 다른 반응 예측인자가 있는지 평가하였다. 방법: 2003년 7월부터 2009년 2월까지 이화여자대학교부속병원에서 진행성 비소세포폐암으로 gefitinib 또는 erlotinib로 치료 받은 환자들의 임상정보를 수집하였다. 중앙 생존기간은 Kaplan-Meier법으로 계산하였다. 결과: 대상 환자는 총 86명이었다(gefitinib군 52명 대 erlotinib군 34명). 나이의 중앙값은 64세였고 53명(62%)이 남자였다. 86명 중 83명에서 반응평가가 가능했으며, 83명 중 35명이 반응을 보였고 12명이 안정성 질환이었으며 36명이 진행성 질환으로, 치료 반응률이 42%였고 질병 조절률이 57%였다. 중앙 추적관찰기간 502일 동안, 진행까지의 중앙기간은 129일이었으며 중앙 생존기간은 259일이었다. 치료 반응률(gefitinib 44% 대 erlotinib 39%, p=0.678), 중앙 생존기간(gefitinib 301일 대 erlotinib 202일, p=0.151) 및 병의 진행까지 기간의 중앙값(gefitinib 136일 대 erlotinib 92일, p=0.672)은 두 군 사이에 차이가 없었다. 두 약제는 비슷한 독성을 보였다. Cox 회귀모형을 이용한 다변수분석에서 선암이 생존과 관련된 독립적인 예후인자였다(상대위험도: 0.487, 95% 신뢰구간: 0.292∼0.811, p=0.006). 아집단 분석 결과 두 약제에 대한 서로 다른 반응 예측인자는 없었다. 결론: Gefitinib와 erlotinib 사이에 반응률, 생존기간, 진행까지의 기간 및 독성에 차이는 없었다. 각 약제에 대한 특이적인 반응 예측인자도 없었다.

다국어 초록 (Multilingual Abstract)

Background: The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), became an attractive therapeutic option for advanced non-small-cell lung cancer (NSCLC). Several studies suggested that there might be some different efficacy or response predictors between gefitinib and erlotinib. We compared the efficacy and toxicity of gefitinib and erlotinib in Korean patients with advanced NSCLC and evaluated specific predictors of response for both gefitinib and erlotinib. Methods: We collected the clinical information on patients with advanced NSCLC, who were treated with gefitinib or erlotinib at the Ewha Womans University Hospital, between July 2003 and February 2009. Median survival times were calculated using the Kaplan-Meier method. Results: Eighty-six patients (52 gefitinib vs. 34 erlotinib) were enrolled. Patient median age was 64 years; 53 (62%) subjects were male. Out of the 86 patients treated, 83 received response evaluation. Of the 83 patients, 35 achieved a response and 12 experienced stable disease while 36 experienced progressive disease, resulting in a response rate of 42% and a disease control rate of 57%. After a median follow-up of 502 days, the median progression-free and overall survival time was 129 and 259 days, respectively. Comparing patients by treatment (gefitinib vs erlotinib), there were no significant differences in the overall response rate (44% vs. 39%, p=0.678), median survival time (301 days vs. 202 days, p=0.151), or time to progression (136 days vs. 92 days, p=0.672). Both EGFR-TKIs showed similar toxicity. In a multivariate analysis using Cox regression model, adenocarcinoma was an independent predictor of survival (p=0.006; hazard ratio [HR], 0.487; 95% confidence interval [CI], 0.292-0.811). Analyses of subgroups did not show any difference in response predictors between gefitinib and erlotinib. Conclusion: Comparing gefitinib to erlotinib, there were no differences in the response rate, overall survival, progression-free survival, or toxicity. No specific predictor of response to each EGFR-TKI was identified.

참고문헌 (Reference)

• 1 Shepherd FA, "Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer" 353 : 123-132, 2005
• 2 Inoue A, "Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammation" 99 : 1679-1684, 2008
• 3 Maruyama R, "Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer" 26 : 4244-4252, 2008
• 4 Lee DH, "Phase II study of erlotinib as a salvage treatment for nonsmall- cell lung cancer patients after failure of gefitinib treatment" 19 : 2039-2042, 2008
• 5 Baselga J, "Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types" 20 : 4292-4302, 2002
• 6 Hidalgo M, "Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies" 19 : 3267-3279, 2001
• 7 Kosaka T, "Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications" 64 : 8919-8923, 2004
• 8 Lind JS, "Lagerwaard FJ. Fatal interstitial lung disease after erlotinib for non-small cell lung cancer" 3 : 1050-1053, 2008
• 9 Parkin DM, "Global cancer statistics, 2002" 55 : 74-108, 2002
• 10 Kim ES, "Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial" 372 : 1809-1818, 2008
• 11 Thatcher N, "Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)" 366 : 1527-1537, 2005
• 12 Chang A, "Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study" 1 : 847-855, 2006
• 13 Makris D, "Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer" 7 : 150-, 2007
• 14 Wong AS, "Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer" 3 : 400-404, 2008
• 15 Ferlay J, "Estimates of the cancer incidence and mortality in Europe in 2006" 18 : 581-592, 2007
• 16 Tsao MS, "Erlotinib in lung cancer: molecular and clinical predictors of outcome" 353 : 133-144, 2005
• 17 Vasile E, "Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib" 3 : 912-914, 2008
• 18 Kim JE, "Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis" 2009
• 19 Sharma SV, "Epidermal growth factor receptor mutations in lung cancer" 7 : 169-181, 2007
• 20 Wu YL, "Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China" 2 : 430-439, 2007
• 21 Li J, "Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes" 13 : 3731-3737, 2007
• 22 Han SW, "Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-smallcell lung cancer patients" 54 : 201-207, 2006
• 23 Non-small Cell Lung Cancer Collaborative Group, "Chemotherapy for non-small cell lung cancer" (2) : CD002139-, 2000
• 24 Korea National Statistical Office, "Annual report on the cause of death statistics 2007" Korea National Statistical Office 2008
• 25 Massarelli E, "A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer" 39 : 55-61, 2003